Navigation Links
Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis
Date:7/20/2011

EASTBOURNE, England, July 20, 2011 /PRNewswire/ --


Daval International announced the completion of the treatment period of its randomised, placebo-controlled, double blind Phase II Study, Treating Patients with Bladder Dysfunction with AIMSPRO in Secondary Progressive Multiple Sclerosis (SPMS). Standard clinical measures and assessment scores recorded on patients who have MS, as well as novel biomarkers will be used to investigate safety, efficacy and response to treatment. Daval expects to have the initial results from this trial by the end of the summer of 2011, with secondary and tertiary outcomes (biomarker data) being made available shortly thereafter. The study completion marks more than 10 years of research and development undertaken by Daval with AIMSPRO.

"Daval is extremely delighted to have completed this very complicated study, which is breaking new boundaries in the quest to find a cure for Secondary Progressive Multiple Sclerosis. This study was an important step towards further understanding how much AIMSPRO could really help people with this disease, for which there is currently no cure or therapy and the results are eagerly awaited" said Professor Syed Haq, MBBS, BSc, PhD, DIC, MCRP(UK) - Chief Scientific Officer at Daval.

About the Study

20 patients participated in this randomised, placebo-controlled, double blind, crossover Phase II trial comparing AIMSPRO with a placebo. Subjects in both the placebo and treatment groups of the trial were given the treatment by subcutaneous injection twice weekly for 4 weeks. After a 6 week wash-out period they crossed over to receive 4 weeks of AIMSPRO or placebo. The primary endpoint of the study is the change in average voided volume at weeks 0 to 4 and weeks 10 to 14 respectively. The secondary endpoints of the study are to assess the efficacy of AIMSPRO as a therapeutic agent for SPMS noting the change in average 24-hour frequency; change in visual acuity and colour vision; change in I-QOL score; change in Kurtzke EDZ assessment; change in MS Impact Scale; change in MS Functional Composite and the change in the MS Walking Scale.

About AIMSPRO®

AIMSPRO is a subcutaneously delivered peptide/polyclonal "large biologic" technically described as hyperimmune caprine serum raised against an inactivated HIV IIIB viral lysate. AIMSPRO has demonstrated powerful and well-tolerated anti-inflammatory capabilities. AIMSPRO exhibits tri-partite functionality by targeting the HPA axis and other pathways and by regulating several key intracellular protein kinases via a highly coordinated mechanism that gives the drug considerable biodiversity and possible application.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic unpredictable neurological disease affecting 2.5 million people worldwide. Multiple sclerosis can cause blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, difficulties with memory and concentration, paralysis, stiffness, bladder problems and blindness. Though most people with multiple sclerosis are diagnosed between the ages of 20 and 40, the unpredictable physical and emotional effects are life-long. The progress, severity, and specific symptoms of multiple sclerosis vary greatly from person to person. Because of the complexity of the disease, the cause and pathology of multiple sclerosis are still not known.

About Daval

DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improves the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

Daval routinely posts information and latest news, including press releases, which may be important to shareholders, health care professionals and patients in the News & Resources section of the company's web site, http://www.davalinternational.com/. The company encourages all interested parties to consult these sections for more information on Daval and its business.


'/>"/>
SOURCE Daval International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Daval International Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
2. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Announces Second Quarter Results
7. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
8. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
9. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
10. Mindray Medical International Announces Second Quarter 2008 Results
11. Singapore to hold international pow-wow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2019)... ... January 17, 2019 , ... ... system software developer, and The Quick Life Science Group (Quick Healthcare and QuickSTAT) ... The platform enables the global cell and gene therapy industry to track products ...
(Date:1/11/2019)... ... 2019 , ... Drawing on over 22 years of software development expertise, the ... will explore some of the key lessons that have driven customer satisfaction with their ... vendors, and find out how to ensure that you continue to be able to ...
(Date:1/8/2019)... ... January 07, 2019 , ... Today AngelMD announced that it ... second investment AngelMD has made into Noninvasix in the past year. , To ... monitor to directly, accurately, and noninvasively measure brain oxygenation in preterm babies in ...
(Date:1/4/2019)... ... January 01, 2019 , ... uBiome, the ... World Economic Forum Annual Meeting January 22-25, 2019 held in Davos-Klosters, Switzerland following ... World Economic Forum Annual Meeting brings together leaders of global society–the heads and ...
Breaking Biology Technology:
(Date:1/7/2019)... ... January 07, 2019 , ... Franz Inc. , ... technology for Knowledge Graphs solutions, announced that it was recognized by Database ... DBTA’s data and information management recognition list includes newer approaches leveraging artificial intelligence, ...
(Date:12/27/2018)... ... December 27, 2018 , ... AxioMed ... at its new Boston facility, and is now raising growth capital to ramp ... expand market share against inferior ball and socket discs. The capital raise is ...
(Date:12/19/2018)... ... ... NDA Partners Chairman Carl Peck, MD, announced today that Deb Koeneman, MS ... Radiological Health (CDRH), has been appointed a Partner in the firm. Ms. Koeneman has ... than 25 years of regulatory experience. In addition to her FDA career, she was ...
Breaking Biology News(10 mins):